Glibenclamide-Loaded Nanoparticles Reduce NLRP3 Inflammasome Activation and Modulate miR-223-3p/miR-7-1-5p Expression in THP-1 Cells

The anti-hyperglycemic drug glibenclamide (Glb) might represent an interesting therapeutic option in human neurodegenerative diseases because of its anti-inflammatory activity and its ability to downregulate activation of the NLRP3 inflammasome. Bi-functionalized liposomes that can cross the blood–b...

Description complète

Détails bibliographiques

Auteurs principaux:	Roberta Mancuso, Lorenzo Agostino Citterio, Simone Agostini, Ivana Marventano, Francesca La Rosa, Francesca Re, Pierfausto Seneci, Marina Saresella, Mario Clerici
Format:	Artigo
Langue:	Inglês
Publié:	MDPI AG 2023-11-01
Collection:	Pharmaceuticals
Sujets:	glibenclamide nanoparticles NLRP3 inflammasome microRNAs rehabilitation
Accès en ligne:	https://www.mdpi.com/1424-8247/16/11/1590
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!